Singapore markets close in 9 minutes

BeyondSpring Inc. (BYSI)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.1601+0.0801 (+3.85%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.0800
Open2.1200
Bid2.1300 x 100
Ask2.2500 x 200
Day's range2.0601 - 2.2498
52-week range0.6530 - 4.0000
Volume33,687
Avg. volume228,388
Market cap84.307M
Beta (5Y monthly)0.17
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    BeyondSpring Files 2023 Annual Report on Form 20-F

    FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (“SEC”) on April 29, 2024. The annual report on Form 20-F, which contains the Company’s audited consolidated financial

  • GlobeNewswire

    BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

    - BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism Data of BeyondSpring’s Lead Asset Plinabulin in Combination with PD-1 Inhibitor and Radiation in a Number of Immune Checkpoint Inhibitor Failed Cancers (Disease Control Rate >50%), Collaboration with MD Anderson - SEED Therapeutics (“SEED”), a BeyondSpring Subsidiary, Achieves Second and Third M

  • GlobeNewswire

    BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

    FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring’s lead asset, plus Etoposide/Platinum (EP) for first-line (1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350]. Cu